[Intraperitoneal administration of Allium macrostemon-derived carbon quantum dots alleviates cisplatin-induced acute kidney injury and restores mitochondrial function in mice].
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
OBJECTIVES: ) administered orally or via intraperitoneal injection in a mouse model of cisplatin-induced acute kidney injury (AKI) and explore the underlying mechanisms. METHODS: -derived CQDs (0.25 mL/day) were administered on a daily basis for 5 consecutive days, and oral CQD solution was given at the dose of 1 mL/day. On day 6, blood samples were collected to measure serum creatinine (CRE) and blood urea nitrogen (BUN). HE staining and transmission electron microscopy (TEM) were used to evaluate kidney tissue structure, mitochondrial morphology, and podocyte injury. Expression levels of renal injury markers (KIM-1 and NGAL) and inflammatory cytokines (IL-6, TNF‑α, and IL-1β) were determined with with RT-qPCR and Western blotting. RESULTS: CQDs treatment groups, kidney/body weight ratios and serum CRE and BUN levels were reduced and the expression levels of KIM-1, NGAL, and inflammatory cytokines were lowered significantly. Histological and ultrastructural analyses revealed more intact renal architecture, reduced inflammatory infiltration, restored mitochondrial morphology, and alleviated podocyte foot process fusion and basement membrane thickening in the two treatment groups, particularly in the intraperitoneal injection group. CONCLUSIONS: -derived CQDs effectively attenuates cisplatin-induced AKI in mice, improves renal function, suppresses inflammatory responses, and repairs mitochondrial damage, thus offering better renal targeting and protective effects for AKI prevention and treatment.
Fields of Study & Subjects
Chemotherapy-induced organ toxicity mitigation
Acute Kidney Injury Research
Chronic Kidney Disease and Diabetes
Publication details
- Journal / source
- PubMed Central
- Volume
- 46
- Issue
- 3
- Pages
- 505–512
- Publication date
- 20 March 2026
- Language
- ZH